SYNGENE.NSE Syngene International Ltd.
143
667.90
17.65
(2.71%)
| Watchers | 143 |
| 52-Wk Low | 649.25 |
| 52-Wk High | 860.25 |
| Market Cap | 266.77B |
| Volume | 674,944.00 |
| 52-Wk High | 860.25 |
| 52-Wk Low | 649.25 |
High single digit to low double digits revenue projections for FY 25: Syngene CEOMoneycontrol • 17 days ago
Management expressed positive long-term outlook for the sector and expressed confidence in Syngene's sustained performance on the back of improved fund flows into US biotech in the latter part of the year.
Share to Feed
Syngene's revenue in the fourth quarter of the reported financial year fell seven percent on a year-on-year basis to Rs 916.9 crore, compared to Rs 994 crore in Q4FY23
CDSL formed robust bullish candlestick pattern on the daily charts with strong volumes. The stock has seen a decisive breakout of consolidation of the recent past sessions and traded well above key moving averages.
Brokerage Goldman Sachs has initiated buy ratings on Syngene International Ltd and Neuland Laboratories Ltd and increased target price to Rs 875 (up 20 percent) and Rs 9100 (up 46 percent), respectively, from current market price. The brokerage house also initiated sell rating on Laurus Labs Ltd with a target price of Rs 350 a share, down 23 percent.
Experts are hopeful of further uptrend towards 22,700-22,800 in the coming sessions, with support at 22,300-22,200 levels, and the volatility index diving to November 2023 lows